Warren P Mason

6PUBLICATIONS
65CO-AUTHORS
Predictive and prognostic markersMining, energy and natural resources lawCancer geneticsMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jul 02, 2026
Temozolomide Versus Radiotherapy as First-Line Therapy for Low-Grade Glioma: Mature Results of a Randomized Phase III Trial (EORTC 22033-26033/NCIC-CTG/TROG/MRC-CTU).

|Mar 16, 2026
Framework for Statistical Parametric Mapping of the Interactions between Glioblastoma Location, Treatment, Prognostic Variables, and Survival Using a Phase III Trial.

Francesco Sanvito, Catalina Raymond, Donatello Telesca

|Dec 01, 2025
STELLAR: Phase III, Randomized, Open-Label Study of Eflornithine Plus Lomustine Versus Lomustine Alone in Patients With Recurrent Grade 3 Astrocytoma.

Howard Colman, Giuseppe Lombardi, Eric T Wong

|Nov 28, 2023
Circulating Oncometabolite 2-hydroxyglutarate as a Potential Biomarker for Isocitrate Dehydrogenase (IDH1/2) Mutant Cholangiocarcinoma.

Cha Len Lee, Grainne M O'Kane, Warren P Mason

|Jun 02, 2023
BRAF Mutations in CNS Tumors-Prognostic Markers and Therapeutic Targets.

Thiago P Muniz, Warren P Mason

Pageof 1

Frequent Collaborators

2 joint publications

Wolfgang Wick

2 joint publications

Olivier Chinot

1 joint publications

Howard Colman

1 joint publications

Giuseppe Lombardi